Good that trial at least started but it is not a mover for SP due to its long duration
- Enrolling 60 patients may be more difficult than 30 patients for adjunct as it is not common condition - as per original protocol - enrollment period was 1 year - so if everything goes right - Jun 2018 - primary out come 100 days after treatment - secondary outcome- follow up 100 and 365 days - so 1 year after last patient dosing
Overall this product will be relevant in 2019 - if company can survive till that time